Related Experiment Video

Updated: Apr 6, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.8K

Adalimumab for the treatment of pediatric Crohn's disease

Federica Nuti1, Gionata Fiorino, Silvio Danese

  • 1Pediatric Unit, Vimercate Hospital, Vimercate, Italy.

Expert Review of Clinical Immunology
|July 28, 2015
PubMed

Insights

Adalimumab (ADA), a biologic therapy, offers new treatment options for pediatric Crohn's disease. This review explores its use, safety, and future in managing this chronic condition in children.

Area of Science:

  • Pediatric Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Inflammatory bowel diseases (IBD) present a significant global health challenge with rising incidence, particularly in pediatric populations.
  • Chronic IBD courses lead to high morbidity and reduced quality of life, necessitating advanced therapeutic strategies.
  • Anti-tumor necrosis factor-alpha (anti-TNF-α) biologics are crucial for managing IBD, especially in cases resistant to conventional treatments.

Purpose of the Study:

  • To review current knowledge on adalimumab (ADA) use in pediatric Crohn's disease.
  • To discuss the safety profile and future therapeutic perspectives of ADA in pediatric IBD management.
  • To highlight ADA's role as a potential early-line therapy in aggressive pediatric Crohn's disease.

Main Methods:

  • Literature review of clinical studies and trials involving adalimumab in pediatric Crohn's disease.
  • Analysis of efficacy and safety data from published research and clinical practice.
  • Synthesis of evidence regarding early-stage intervention with ADA.

Main Results:

  • Adalimumab (ADA) is now approved for pediatric Crohn's disease, offering an alternative to infliximab and a potential first-line biologic therapy.
  • Evidence supports earlier introduction of ADA in pediatric patients with aggressive or extensive disease.
  • Ongoing research is crucial for a comprehensive understanding of ADA's long-term safety and efficacy in this population.

Conclusions:

  • Adalimumab represents a significant advancement in treating pediatric Crohn's disease, providing a valuable therapeutic option.
  • The potential for early intervention with ADA warrants further investigation to optimize patient outcomes.
  • Continued research into safety and long-term effectiveness is essential for guiding clinical practice.

Keywords:
adalimumabanti-TNF-α antibodiesefficacyinflammatory bowel diseasepediatric Crohn’s diseasesafety

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

597
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.4K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
698
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
764
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
653
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
957
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
651
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.5K